Background. Renal transplant recipients (RTRs) have an increased risk of developing nonmelanoma skin cancers (NMSCs). The aims of this study were to determine the incidence and subsequent history of NMSCs in RTRs, together with risk factors. 14.2, 22.9) from transplant, as estimated by survival analysis. Individual predictors of first NMSC in RTRs were older age at first transplant (P < 0.0001), male sex (P = 0.006) and initial immunosuppression regimen (P = 0.001); only age (P < 0.0001) and male gender (P = 0.003) were significant predictors in a joint model.
Introduction
Advances in the field of renal transplantation have added years to many patients' lives [1] . The reduced graft rejection, and increased survival of these patients, is largely due to the introduction of more powerful immunosuppressive drugs [1] . While infections and cardiovascular disorders used to be the main cause of death, NMSCs are now one of the commonest causes of death in RTRs [2] . Squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) account for >90% of all skin cancers in renal transplant recipients (RTRs) [3, 4] . The incidence of SCC and BCC in RTRs appears to be higher (up to 250-fold) than in the normal population [5] , and the cumulative incidence of SCC and BCC 20 years after transplantation has been reported to reach 82% in Queensland, Australia [6] , and 41% in the Netherlands [7] . RTRs tend to develop larger and more extensive NMSCs [8] , and SCCs appear to have a more aggressive phenotype in transplant recipients than in immunocompetent individuals (ICIs) [9] [10] [11] . Histologically, these tumours have adverse prognostic characteristics, such as high tumour cell proliferation rate and high invasiveness. In RTRs, adverse outcomes associated with SCCs include rapid growth, local and distant metastases, local recurrence (often within six months after excision), death from relapse, or decreased quality of life from numerous new primary skin cancers [8, 12, 13] . It is still poorly understood why some RTRs develop NMSC earlier, more frequently and with more invasive phenotype than others.
The incidence of NMSCs is high in New Zealand with an estimated 64 000 new cases diagnosed every year, out of a population of 4.3 million [14] . The cost of skin cancer treatment and the mortality rate from skin cancer are among the highest in the world per capita [15] with NMSCs being responsible for 111 deaths in 2002 [16] . The main risk for NMSCs is sun exposure [17, 18] . The Canterbury region is at latitude 42
• S and has an average of 2000 sunshine hours annually. There are several clinical studies reporting the incidence of NMSCs in RTRs in other countries [3, 6, 7, [19] [20] [21] . However, this is the first study to assess the incidence and predictors of first and subsequent NMSCs in a New Zealand RTR population.
The aims of this study were (1) to determine the incidence of NMSCs in RTRs in the Canterbury population, (2) to investigate the subsequent history of NMSCs in RTR and (3) to identify any subgroups of RTRs at higher risk of NMSCs.
Subjects and methods
The nephrology clinical database (Proton TM Clinical Computing Ltd) was searched for data on patients who received a renal transplant between July 1972 and March 2007, and were followed up at Christchurch Hospital, New Zealand. All NMSCs and significant clinical events, including death, were routinely recorded in the clinical database. RTRs with NMSC prior to transplant or whose transplant never functioned were excluded. The sample definition meant that the patients included in the analysis were living in the same geographical region, but the extent of their personal sun exposure was not known.
The hospital case notes and histopathology reports of 96 RTRs who developed at least one NMSC were reviewed to collect clinicopathological data, details of treatment, and follow-up including survival, new NMSCs and cause of death. Two patients with incomplete follow-up were excluded from analysis after the first NMSC. The date of final follow-up was the 1st of September 2007.
The maintenance immunosuppression regimens used were: 1972-1983 prednisone/azathioprine; 1984-1997 prednisone/azathioprine/ cyclosporine or prednisone/cyclosporine; 1998-2007 prednisone/ mycophenolate mofetil/cyclosporine for all except for three patients who were on prednisone/mycophenolate/tacrolimus. Acute allograft rejections were treated with pulse methylprednisolone 0.5 to 1.0 g daily for three days and OKT3 (muromonab) for steroid-resistant rejection. The effect of the type of immunosuppression regimen on development of first NMSC was analysed in 371 RTRs. Thirteen patients were excluded, two for missing data, eight on Prednisone/Cyclosporine (used only in 1984 and 1985) and three on prednisone/mycophenolate/tacrolimus (two in 2005 and one in 2007).
All patients were under the care of a single nephrology department clinic. The nephrology centre in Christchurch Hospital manages all RTRs in the region in collaboration with on-site dermatologists and plastic surgeons. Therefore, integration of data from all three departments in one centre enabled thorough assessment of skin cancers in RTRs in the Canterbury population.
Statistics
Samples were described using frequencies, means and medians. Survival analysis was used for the incidence of first NMSC following first renal transplant and for analysis of time from discovery of first NMSC to second NMSC. Kaplan-Meier curves were compared using the Wilcoxon test. Cox proportional hazards models were used to look at predictors singly and together. Predictors were derived from demographic data and those already proposed in the literature. Poisson regression was used to model the number of subsequent NMSC per year after the first NMSC. All analyses were carried out in SAS 9.1 (www.sas.com) using PROC MEANS, PROC FREQ, PROC LIFETEST, PROC PHREG and PROC GENMOD.
Results

Demographics, clinical characteristics and incidence of NMSCs in Canterbury RTRs
Characteristics of 384 RTRs transplanted between July 1972 and March 2007 and followed up in Christchurch Hospital are shown in Table 1 . The mean age at transplantation was 41.5 years (SD = 14.3), with 30% of patients over 50 years old and 25% of patients less than 30 years old. The median follow-up until the development of first NMSC or censoring was 5.3 years (range 0.01-33.4), with a total of 2815.4 person-years observed.
From the cohort of 384 RTRs, 96 developed at least one NMSC. Therefore, the incidence of first NMSC was 96 in 2815.4 person-years, which corresponds to 3.4 per 100 person-years (95% CI 2.8, 4.2). The mean age at diagnosis of the first NMSC for the 96 RTRs was 52.0 years (SD = 11.64): 60-75 years for 31% of RTRs, 50-59 years for 27% followed by 40-49 years for 26% and <40 years for 16% (separate analysis). Two patients with incomplete follow-up were excluded from analysis. All patients were Caucasians.
On average 14 NMSCs were excised per patient (range 1-208 per patient). In 63% of RTRs who developed at least one NMSC, invasive SCC was the first cancer to present. The overall ratio of SCC to BCC was 1.2:1. Five patients required finger or ear amputations. Ten years after first discovery of NMSC, the Kaplan-Meier estimate of the percentage who died from metastatic NMSC was 15% (95% CI 7%, 29%), with all other deaths treated as censored. The overall percentage of those who had died from any cause was 45% (95% CI 33%, 58%). The demographics and clinical characteristics of the 94 patients are summarized in Table 1 .
Based on survival analysis, the median time to development of the first NMSC in RTRs was 18.3 years (95% CI 14.2, 22.9). Twenty-five percent of RTRs had developed NMSC by 10 years (10.1 years, 95% CI 7.5, 11.8) ( Figure 1A) .
Predictors of the incidence of NMSCs
The time from first transplant to discovery of first NMSC overall, by age and by sex is shown in Figure 1 . The results of Cox proportional hazards models are presented in Table 2 .
Analysis for each predictor separately showed a significant effect of age at first transplant: with increasing age at the time of renal transplant there was earlier development of NMSC and the instantaneous risk of NMSC increased by 60% for each additional decade of age (HR = 1.6, 95% CI 1.4, 1.9) ( Table 2 ). The median time to the development of first NMSC after transplant was 22.3 years for those aged under 30; 19.9 years for those aged 30-39, 15.2 years for those aged 40-49 and 11.8 years for those aged 50 or over ( Figure 1B) .
Male sex was associated with earlier development of NMSCs than female sex. Fifty percent of males developed NMSC within 16.9 years and females within 22.3 years c Age divided by 10 so that HR is the hazard ratio for an increase in age of one decade. d PAC (prednisone/azathioprine/cyclosporine), PA (prednisone/azathioprine), PMC (prednisone/mycophenolate/cyclosporine). Overall P-value for immunosuppression on its own was P = 0.001. e Overall P-value for donor type on its own was P = 0.18.
( Figure 1C ). In the joint model the hazard ratios for age and sex were very close to those calculated for each individually ( Table 2) . More recent immunosuppression regimens appeared to be associated with a higher risk of NMSC, with association of a more rapid onset of NMSC in patients on prednisone/mycophenolate/cyclosporine (PMC), followed by prednisone/azathioprine/cyclosporine (PAC) and prednisone/azathioprine (PA) ( Table 2 ). There was a trend towards an increased risk of NMSCs for RTRs receiving renal transplants from living unrelated donors, compared with those who received kidney transplants from deceased donors ( Table 2 , single predictors).
However, when analysed using a joint model, the hazard ratios for immunosuppression regimen and for donor type were not significant. The apparent effect of immunosuppression regimen was accounted for by an increase in the mean age of transplant patients: for PA the mean age at transplant was 37.2 years (SD = 13.2), for PAC 40.7 years (SD = 14.9) and for PMC 46.7 years (SD = 13.3), with F = 15.3, df = 2367, P < 0.0001. There was also a small increase in the percentage of males across the regimens: PA 54.4%, PAC 56.5%, PMC 65.0%. Similarly, the donor types also differed in the mean age at first transplant: for deceased donors the mean recipient age was 42.4 years (SD = 14.2), for living related donors 36.2 years (SD = 14.9) and living unrelated 47.0 years (SD = 9.0) (F = 8.3, df = 2, 367, P = 0.003).
Second and subsequent NMSCs in RTRs
Kaplan-Meier survival analysis indicated that virtually all RTRs diagnosed with first NMSC will develop further NMSCs. The median time to the development of second NMSC was 2.2 years (95% CI 1.4, 3.0) (Figure 2 ). On average, patients were observed for 7.0 years after the first discovery of NMSC (SD = 4.5 years).
After development of a first NMSC, there was no sex difference in the risk of a second NMSC, either considering sex alone (male: female HR = 1.03; 0.65, 1.66, P = 0.89) or taking into account age at first transplant (HR = 1.18; 0.73, 1.91, P = 0.51) (separate analysis).
The overall annual incidence for a new NMSC was 1.67, 95% CI = 1.32, 2.11 (1081 NMSC in 647 person-years), after exclusion of one patient with 11 NMSCs at first discovery. Table 3 shows the association between prediction factors such as the annual rate of NMSC after the first NMSC was discovered, for each predictor on its own and for a joint model. The older a patient was at first renal transplant the higher the annual rate of new NMSCs after the diagnosis of first NMSC, with the rate increasing by a multiple of 1.23 for each additional decade of age (P = 0.009). Advanced age at diagnosis of first NMSC was similarly associated with a higher rate of further NMSCs (P = 0.01) ( Table 3 ). In the joint model age at first transplant remained highly significant with risk increasing by 1.39 per decade. Sex and the number of NMSC at first discovery showed non-significant trends (P = 0.10, 0.11). Relative to the era before 1996, patients whose first NMSC was discovered in 2002-2007 had a lower annual rate of subsequent NMSCs.
Even in the joint model for annual rates there was a clear overdispersion (deviance/df = 13.5) relative to a Poisson model. This indicates that there was still unexplained heterogeneity in rates across the patients, presumably because factors such as actual sun exposure or skin type were not known, therefore could not be included.
Discussion
Despite the high overall incidence of skin cancer in New Zealand, and anecdotal evidence for a continuing increase in the number of potentially serious NMSCs in the renal transplant population, the number of RTRs affected in New Zealand is unknown [22] . The incidence of skin cancers in RTRs has been reported from studies in Europe [23] [24] [25] [26] [27] and Australia [3, 6] . The cumulative incidence of SCC and BCC twenty years post-transplantation has been reported to have reached 82% in Queensland, Australia [6] , 40% in the UK [27] , 41% in the Netherlands [7] and 15.3% in Italy [28] . The cumulative incidence at 10 years posttransplantation has been reported to be 18% in Canada [29] , 10% in the Netherlands [7] , 24.8% in the UK [19] and 45% in Queensland, Australia, at 11 years [3] . However, comparison of the results of such studies is hampered by the different study methodologies and the lack of consistent definitions of prevalence and incidence used for reporting NMSCs after renal transplantation. In this study, the cumulative incidence at 10 and 20 years post-transplant by comparison was 24.2% and 54.4% respectively, an incidence between that of Queensland [6] and the UK [27] . The cumulative incidence shown in Figure 1A suggested that NMSCs will occur in all RTRs, if they survive long enough.
NMSCs are poorly reported world-wide. Registry data are limited by the completeness of case reporting and they greatly underestimate the true rate of NMSC in RTRs [6] . As RTRs develop multiple NMSCs, clinicians tend to stop recording subsequent skin cancers. Therefore, data on how many skin tumours develop in a given transplant population are still missing [30] . Patients are often treated by a number of practitioners, and it takes many years to accumulate a sufficient number of long-surviving patients to allow an assessment of long-term risks. However, in this study integration of data from the dedicated nephrology database of RTRs at Christchurch Hospital, New Zealand, and case notes enabled detailed assessment of the number of skin cancers and potential risk factors. The discrete RTR population was stable and followed up in a single centre, under the same environmental influences, which play a very important role in determining NMSC incidence [31] . However, the epidemiology of NMSCs in the background population was not obtained as there is no national nonmelanoma skin cancer registry in New Zealand available.
The two most important risk factors for NMSCs in the transplant population are the amount of sun exposure and age at transplantation [28, 32] . This study has demonstrated a relationship between the age at transplantation and the incidence of first or second NMSC. In agreement with other studies, this study showed a predominance of male patients who develop NMSC [18, 20, 23, 29, 33] .
While in immunocompetent individuals (ICIs), the ratio of SCC to BCC is approximately 1:4 [34] , in RTRs this has been reported to vary from 0.9:1 to 15:1 [7, 21, 24, 35, 36] , with a ratio of SCC to BCC of 3.1:1 in Queensland, and lower ratios reported in some parts of Europe [20, 21] . In this cohort, the SCC/BCC ratio was 1.2:1 which is the same ratio reported in New Zealand RTRs almost 25 years ago [22] , preceding the use of calcineurin inhibitors (cyclosporine/tacrolimus). The ratio we observed was more similar to the French and Spanish populations [21, 35] . Differences in the ratio may be explained by differences in factors such as annual sunshine hours, UV index (latitude, degree of pollution, ozone layer integrity), different skin types (genetic background) and outdoor activities [5, 20, 23, 37] .
SCCs are reported to be more aggressive in RTRs with a higher risk of metastasis and poorer prognosis than in the general population [2, 5, [38] [39] [40] . SCCs metastasize in 5-8% of RTRs, a rate that is approximately 10-fold higher than that seen in the immunocompetent population [5, 41, 42] . SCC-specific mortality has been reported to range from 1.5% to 8% [27, 39, 41, 43] . The mortality rate secondary to metastatic cutaneous SCC in our transplant population was 15%, which is higher than reported by other centres. This may be explained by longer and more intensive follow-up, which contributes to a comprehensive collection of data. The high mortality rate from metastatic SCCs and high rate of subsequent NMSCs found in this study argue for close surveillance of RTRs for NMSCs, with prompt excision on discovery. The most effective way to reduce morbidity and mortality from NMSCs is to excise tumours promptly [39] . The data suggest that surveillance should focus on older males, and intensify with time since transplantation. Furthermore, we also found a higher average number of NMSCs per patient than previously described [3, 12, 23, 44] . The subsequent rate of NMSCs following the diagnosis of the first NMSC was 1.7 lesions per year with a median of 2.2 years to a diagnosis of a second NMSC. This suggests that RTRs who have developed their first NMSC should remain under close surveillance for the rest of their lives and should be considered for modification of their immunosuppression regimen.
The role of immunosuppressive drugs in the development of NMSCs is not clear and different studies provide conflicting data [3, [45] [46] [47] [48] [49] [50] . While chronic immunosuppression per se may impair defence mechanisms against cutaneous malignancies, some agents may be carcinogenic [51] [52] [53] . Most studies report the intensity of immunosuppression rather than the mechanism of action of particular agents as associated with increased risk of NMSC [3] . Duration of immunosuppression has been shown by others to be a significant risk factor predisposing to NMSC [8, 18, 19] . Recently, sirolimus, which is characterized by both antineoplastic and immunosuppressive effects, was shown to reduce risk of malignancy, including skin cancers post-transplant [54] . In the current study, once gender and age were accounted for, there was no association with immunosuppression regimen and development of first NMSC.
Few data exist on the development of subsequent NMSCs in RTRs [55] . In some studies, the reported average time to the development of a second NMSC ranged from 15 to 41 months [5, 12, 18] . In comparison, the current study showed an average time of 26 months until development of a second NMSC. The first dermatology clinic dedicated to regular skin cancer surveillance in RTRs was established in Christchurch Hospital in 2006, following increased recognition of the importance of NMSCs. The annual rate of subsequent NMSCs was lower for patients who first developed NMSC after 2001. It is possible that this reflects a changing rate over the time since the first NMSC discovery, but may also reflect lead-time bias. Within this period no change was made to the immunosuppression regimen.
In conclusion, this study showed the risk of nonmelanoma skin cancers increases with time from renal transplant. Three single predictors of nonmelanoma skin cancers in renal transplant recipients were identified: older age at first transplant, male gender and initial immunosuppression regimen. However, in a joint model, only age and being male predicted onset of nonmelanoma skin cancer. Once RTRs have developed their first nonmelanoma skin cancer, these patients develop further NMSCs at a rate of 1.7 per year.
Therefore, renal transplant recipients require close surveillance and prompt treatment of nonmelanoma skin cancers for the rest of their lives. Importantly, review of immunosuppression regimen is vital.
